|
|
FOR IMMEDIATE RELEASE
Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc.
508-359-4005, x108
Pico-Tesla expands operations to East Coast
“We are pleased with our fast start to the new year.”
Allen Braswell, CEO
LITTLETON, Colo., and CLEARWATER, Fla., March 15, 2010 — Pico-Tesla, The
Magneceutical™ Therapy Company, announced today that it has expanded its operations by
opening an East Coast headquarters near Tampa, Florida.
“We have gotten off to a very fast start in 2010,” said Allen Braswell, CEO of Pico-Tesla. “Of
course, we are pleased that new investors have determined that Pico-Tesla has a significant
opportunity ahead of it. But we also are very excited about our new operations in Tampa Bay,
which we believe will allow us to accelerate enrollment in our two ongoing clinical trials, one for
Parkinson’s Disease and the other for type 2 diabetes.”
The purpose of the ongoing Phase III clinical trial is to demonstrate the efficacy of
Magneceutical™ Therapy as an adjunctive therapy to improving aspects of health and quality of
life that are relevant to patients with Parkinson's Disease. Pico-Tesla intends to submit the Phase
III data and analysis via a 510(k) de novo application to obtain FDA clearance to sell the device
in the United States. The Phase III clinical trial was designed by principal investigator Rajeev
Kumar, M.D., a movement disorder specialist and medical director of the Colorado
Neurological Institute Movement Disorder Center, Englewood, Colo.
Pico-Tesla also has been enrolling patients in a randomized, double-blinded, placebo-controlled
Pilot Study of persons who have type 2 diabetes, the most common form of diabetes. The Pilot
Study seeks to determine whether the application of magnetic fields generated by the Company’s
patented Resonator™ system can be effective as an adjunctive therapy to oral medications in
reducing hemoglobin A1c levels. The protocol for the Pilot Study was developed in consultation
with Michael McDermott, M.D., Director, Endocrinology and Diabetes Practice, University of
Colorado Health Science Center, Aurora, Colo.; and with Mitchell Gershten, M.D., an internist
and staff physician at Saint Mary’s Hospital in Grand Junction, Colo.
Pico-Tesla’s Magneceutical™ Therapy involves the use of an extremely low-level
electromagnetic field (EMF) applied by a specially designed device—the Resonator™, invented
by Dr. Jerry I. Jacobson, along with proprietary therapeutic protocols—intended to improve
a number of the signs and symptoms of Parkinson’s and other diseases, including Type 2
Diabetes.
Privately held Pico-Tesla Magnetic Therapies is an emerging medical technology company with
operations at: 4700 140th
Avenue North, Suite #101, Clearwater, FL 33762.
CAUTION: The Resonator™ device is an Investigational Device limited by federal (or United States) law
to investigational use. The Resonator™ device is not for sale, nor is the Magneceutical® Therapy generally
available outside of Investigational Review Board (IRB)-approved clinical studies.
|
